Mimetogen Pharmaceuticals Completes Key Equity Financing for Ophthalmology Drugs

MONTRÉAL, Québec--(BUSINESS WIRE)--Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately held drug development company announced today that it has successfully completed an equity financing, co-led by Boston-based VIMAC Milestone Medica Fund and Montréal-based iNovia Capital. The Company has also completed discussions with the FDA concerning both pre-clinical and clinical development of its lead compound to treat dry eye syndrome.